Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, we did not find any association of polymorphism of XRCC1 Arg399Gln (OR = 1.56; 95% CI: 0.32-7.82) and XPD Lys751Gln (OR = 0.46; CI: 0.10-2.19) with GC risk in the study population.
|
30225185 |
2018 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The effect of the XRCC1 gene homozygosity, particularly Arg/Arg, on the risk for stomach cancer was elevated by a high intake of vegetable oils and salt.
|
29020930 |
2017 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, we suggest that the XRCC1 gene Arg194Trp polymorphism is associated with gastric cancer susceptibility in the Chinese population.
|
27706710 |
2016 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic variability of XRCC1 influences the treatment outcome of gastric cancer.
|
26909965 |
2016 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings demonstrated that XRCC1 gene rs25487 polymorphism might play a leading role in pronounced susceptibility to gastric cancer in Han Chinese.
|
26590607 |
2016 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the effects of XRCC1 gene and clinicopathological characteristics on survival of stomach cancer patients in Thailand.
|
26320504 |
2015 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis aimed to obtain a comprehensive and reliable assessment of the relationships between XRCC1 Arg399Gln and XPD Lys751Gln polymorphisms and the clinical outcomes of gastric cancer (GC) patients treated with oxaliplatin-based chemotherapy.
|
24590266 |
2014 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis aimed to summarize published data about the association between two SNPs of XRCC1 (Arg194Trp and Arg399Gln) and treatment outcomes of patients with advanced gastric cancer.
|
24465544 |
2014 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrated the role of XRCC1 in repair of cisplatin-induced DNA lesions and acquired cisplatin resistance in gastric cancer by using cisplatin-sensitive gastric cancer cell lines BGC823 and the cisplatin-resistant gastric cancer cell lines BGC823/cis-diamminedichloridoplatinum(II) (DDP).
|
24525731 |
2014 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to evaluate the associations between XRCC1 genetic variants and gastric cancer susceptibility in Chinese Han population.
|
24779987 |
2014 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results indicated that the A allele of the XRCC1 Arg399Gln polymorphism was significantly associated with poor OS (HR = 1.40; 95%CI = 1.04-1.90) of gastric cancer but not for platinum-based chemotherapy response or PFS.
|
24634242 |
2014 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis indicates that genetic polymorphism of the XRCC1 Arg399Gln and Arg280His do not have an association with gastric cancer risk.
|
25335737 |
2014 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.
|
23604281 |
2013 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings demonstrated that the genetic variant Arg280His in XRCC1 may contribute to cancer progression and that XRCC1 Arg194Trp variants may act as a favorable prognostic indicator of resected GC, particularly among the diffuse-type GC.
|
23425027 |
2013 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of XRCC1 gene and susceptibility to gastric cancer in Chinese Han population.
|
23919819 |
2013 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to detect the potential association of genetic variants in XRCC1 gene with gastric cancer risk in Chinese Han population.
|
23983608 |
2013 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Individuals carrying the XRCC1 Trp/Trp or Arg/Trp variant genotype were at significantly increased risk of noncardia GC (adjusted OR, 1.48; 95% CI, 1.00-2.17), after adjustment for family history of cancer, drinking, and smoking.
|
23317230 |
2012 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For XRCC1 Arg194Trp polymorphism, we only found the Trp/Trp genotype carriers might be at high risk of GC (TT vs. CC+CT: OR = 1.31, 95%CI = 1.04-1.65).
|
21604176 |
2012 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the XRCC1 Arg399Gln polymorphism is not a risk factor for developing gastric cancer.
|
23212324 |
2012 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ADPRT Val762Ala and XRCC1 Arg194Trp polymorphisms and risk of gastric cancer in Sichuan of China.
|
22901183 |
2012 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and gastric cancer risk: A HuGE review and meta-analysis.
|
21216841 |
2011 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
XRCC1 194Trp allele significantly increased the risk of gastric cancer and also associated with risk of gastric cardia carcinoma and promoted distant metastasis of gastric cancer.
|
20863780 |
2011 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
XRCC1 codon 194 Trp carrier status is correlated with more aggressive biological behavior of GC, such as venous invasion, and the GSTT1 null genotype is associated with better survival in GC patients.
|
21378360 |
2011 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphic variants of base excision repair (APE1-D148E, XRCC1-R194W, XRCC1-R399Q and OGG1-S326C), nucleotide excision repair (XPC-PAT, XPA-23G>A, ERCC1-19007T>C and XPD-L751Q), recombination (XRCC3-T241M) and alkylation damage reversal (MGMT-L84F) were tested for their potential role in the development of GC by using logistic regression models.
|
20817763 |
2010 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The positive rate of XRCC1 in patients with well/moderately differentiated gastric cancer was significantly higher than patients with poorly differentiated gastric cancer (P < 0.05).
|
21091896 |
2010 |